- Home
- ZTEK vs ATOS Comparison
ZTEK vs ATOS Comparison
Compare ZTEK & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- ATOS
- Stock Information
- Founded
- ZTEK 2008
- ATOS 2009
- Country
- ZTEK Canada
- ATOS United States
- Employees
- ZTEK N/A
- ATOS N/A
- Industry
- ZTEK Major Chemicals
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- ATOS Health Care
- Exchange
- ZTEK Nasdaq
- ATOS Nasdaq
- Market Cap
- ZTEK 91.6M
- ATOS 107.2M
- IPO Year
- ZTEK N/A
- ATOS 2012
- Fundamental
- Price
- ZTEK $0.89
- ATOS $0.81
- Analyst Decision
- ZTEK
- ATOS Strong Buy
- Analyst Count
- ZTEK 0
- ATOS 3
- Target Price
- ZTEK N/A
- ATOS $6.17
- AVG Volume (30 Days)
- ZTEK 820.9K
- ATOS 485.8K
- Earning Date
- ZTEK 08-14-2025
- ATOS 08-12-2025
- Dividend Yield
- ZTEK N/A
- ATOS N/A
- EPS Growth
- ZTEK N/A
- ATOS N/A
- EPS
- ZTEK N/A
- ATOS N/A
- Revenue
- ZTEK $678,078.00
- ATOS N/A
- Revenue This Year
- ZTEK N/A
- ATOS N/A
- Revenue Next Year
- ZTEK N/A
- ATOS N/A
- P/E Ratio
- ZTEK N/A
- ATOS N/A
- Revenue Growth
- ZTEK 2519.47
- ATOS N/A
- 52 Week Low
- ZTEK $0.50
- ATOS $0.55
- 52 Week High
- ZTEK $1.84
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- ZTEK 56.55
- ATOS 54.45
- Support Level
- ZTEK $0.65
- ATOS $0.81
- Resistance Level
- ZTEK $0.91
- ATOS $0.80
- Average True Range (ATR)
- ZTEK 0.10
- ATOS 0.03
- MACD
- ZTEK 0.03
- ATOS 0.01
- Stochastic Oscillator
- ZTEK 42.77
- ATOS 90.59
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.